Pharmaceutical research and development stands at a pivotal juncture, grappling with a paradoxical shift in drug modality approvals that signals a fundamental transformation in the industry’s approach to medicine. While biologics are experiencing rapid market growth and are projected to surpass small molecule sales by 2027, recent data reveals an unexpected resurgence in small molecule approvals. In 2025, small molecules constituted 65% of novel drug approvals by the U.S. Food and Drug Administration (FDA), a notable increase from 56% in both 2023 and 2024. This apparent contradiction underscores a critical evolution: the historical binary choice between small and large molecules is dissolving, giving way to a complex, hybrid-driven landscape where convergence, rather than competition, defines the cutting edge of drug discovery.
Evolving Market Dynamics and the Modality Paradox
The global pharmaceutical market has witnessed a significant shift in its composition over the past decade. In 2018, the market was valued at an estimated $828 billion, with small molecules accounting for 69% of sales and biologics for 31%. By 2023, the market had expanded to $1.344 trillion, with small molecules representing 58% and biologics 42%. The robust growth of biologics, which are expanding at three times the rate of their chemical counterparts, has led many analysts to forecast their market dominance by 2027. This rapid ascent is fueled by their unparalleled specificity and efficacy in addressing previously "undruggable" targets.
However, the recent uptick in small molecule approvals, as highlighted by the FDA’s 2025 figures, suggests a more nuanced reality. This resurgence is not a regression but rather a testament to significant technological advancements, including AI-accelerated discovery processes, novel chemical approaches, and innovations in drug delivery. Murray Aitken of IQVIA noted in their 2024 report on global R&D trends that while biologics undeniably drive market value, small molecules are undergoing a "technological upgrade" through breakthroughs in induced proximity and oral delivery. This dynamic indicates that rather than one modality displacing the other, both are evolving and finding new applications, often in concert.
The Dawn of Precision Medicine and AI-Driven Discovery
The overarching trend reshaping pharmaceutical R&D is the decisive shift from broad-spectrum therapies to highly targeted precision medicine. This paradigm change is fundamentally driven by monumental advancements in genomics, a deeper understanding of target biology, and the transformative power of artificial intelligence (AI). Researchers are now equipped with tools that allow for the identification and attack of diseases with unprecedented specificity, moving beyond generalized treatments.
Andreas Matern, Vice President of Professional Services at Elsevier, articulates this shift succinctly: "It’s no longer trying to shotgun blast a whole bunch of things, but instead trying to sniper and be really tight in what we’re attacking." This philosophy underpins current drug discovery efforts, where pharmaceutical companies are increasingly leveraging extensive biological intelligence to inform modality selection before committing to development. This involves a comprehensive understanding of the specific target, the genetic landscape of the disease, and the precise patient population that stands to benefit most.
AI’s role in this revolution is multifaceted and profound, compressing timelines, generating novel hypotheses, and guiding modality selection with unprecedented efficiency. Platforms like AlphaFold are revolutionizing structural biology by predicting protein structures, which is critical for drug design. Generative chemistry leverages AI to design novel chemical entities with desired properties, while large language models are sifting through vast proprietary and public datasets to unlock new insights into disease mechanisms and therapeutic interventions.
Daphne Koller, CEO and founder of Insitro, emphasized the critical need for AI to enhance the success rate of drug programs at the Danaher Summit: "Most programs fail in the clinic because of the early stages of the decision-making process. The focus of the next few years needs to be on increasing the success rate (the yield), rather than just efficiency. AI must help us select the right therapeutic hypotheses and the right patient populations from the start." This sentiment highlights AI’s potential to de-risk early-stage development, making the entire R&D pipeline more productive.
Defining the Modalities: A Deeper Dive
Understanding the distinct characteristics of small and large molecules is crucial to appreciating their evolving roles and the benefits of their convergence.
Small Molecules: These are chemically synthesized compounds, typically characterized by a molecular weight below 900 Daltons. Their diminutive size allows them to readily cross cell membranes, granting access to intracellular targets—a significant advantage for diseases originating within cells. Small molecules generally offer several practical benefits: they are often orally bioavailable, stable at room temperature, and can be manufactured at a large scale, contributing to lower production costs. They also benefit from well-established regulatory and manufacturing pathways, making their development often more predictable. Historically, small molecules have formed the bedrock of pharmaceutical treatment.
Large Molecules (Biologics): In contrast, large molecules are derived from living organisms, encompassing a diverse range of entities such as cells, proteins, and nucleic acids. Structurally, they are far more complex than small molecules, typically weighing over 1,000 Daltons. Their size generally prevents them from easily crossing cell membranes, necessitating administration via injection or infusion. Examples include monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), mRNA therapies, CAR-T cell therapies, and engineered peptides like GLP-1 agonists. Biologics are renowned for their exquisite specificity to their targets, which often translates into reduced off-target toxicity. However, their complexity poses challenges in manufacturing and storage, frequently requiring cold chain logistics.
The fundamental choice between these modalities is intrinsically linked to target biology. Key considerations include the desired specificity, the nature of the patient population, and whether the target is intracellular or extracellular. Increasingly, sophisticated data platforms are central to addressing these questions, aggregating published research, clinical trial data, and pipeline intelligence to inform strategic decisions. As Matern stated, "The choice of modality — whether I use a small molecule or any number of the large molecules — really comes down to understanding your target, understanding the biology."
Historically, a significant limitation of small molecules was their inability to target approximately 80% of the human proteome, often deemed "undruggable" due to the absence of well-defined binding pockets. This limitation was a primary driver for the development of biologics, which can engage targets inaccessible to traditional small molecules. However, the emerging landscape sees this limitation being actively challenged by new small molecule technologies, blurring the lines between what was once a clear binary.
Market Landscape and R&D Investment: A Dual Ascent
The global small molecule drug discovery market was valued at $61.9 billion in 2025 and is projected to reach $103 billion by 2031, reflecting sustained growth despite predictions of biologic dominance. This growth is buoyed by the aforementioned AI-accelerated discovery and lead optimization, as well as innovations in oral delivery. This trend is further supported by IQVIA’s 2024 data, which highlights a "technological upgrade" in small molecules, particularly through induced proximity and advancements in oral delivery.
Concurrently, the global biologics market, which reached $349 billion in 2023, is forecast to achieve a staggering $1.077 trillion by 2035. This expansion is propelled by several factors: the increasing approval of ADCs, the rapid diversification of mRNA platform technology beyond vaccines, the scaling of CAR-T and other cell/gene therapies, and the growing regulatory traction for RNA-based therapies like siRNAs and antisense oligonucleotides (ASOs). While biosimilar competition is intensifying as blockbuster biologics lose patent protection, innovation pipelines remain robust, continuously pushing the boundaries of what biologics can achieve.
The strategic approach to modality investment varies significantly across the pharmaceutical industry, heavily influenced by a company’s size, existing infrastructure, and overarching strategic goals. Large pharmaceutical companies often maintain diversified portfolios, spanning small molecules, biologics, and emerging modalities. This diversification allows them to absorb risks across multiple therapeutic areas and leverage extensive manufacturing infrastructure to scale various drug types. In contrast, biotech companies typically adopt a platform-driven model, specializing in a particular modality or technology. While this approach carries a higher risk concentration, it often fosters faster, more focused innovation.
Matern elaborated on this dynamic: "Large pharma has the privilege of running diversified portfolios across molecules, biologics – maybe they can try newer modalities so they can balance some of that risk across different therapeutic areas. Whereas smaller biotechs are often built around a specific platform… a lot of biotechs are built around, ‘we have a really clever way of doing this modality – so what can we point this modality at?’" This interplay between large pharma and specialized biotechs is a key driver of the robust deal-making environment, with large players frequently acquiring or licensing biotech platforms to gain access to novel modalities without needing to build the capabilities from the ground up.
The Small Molecule Renaissance: A New Era of Innovation
For years, the prevailing narrative in pharma was that biologics would inevitably displace small molecules as the dominant drug modality. This narrative is now being fundamentally challenged by a remarkable renaissance in small molecule R&D. A confluence of AI-driven discovery, groundbreaking novel chemical approaches, and significant innovations in delivery is opening up previously inaccessible target classes, redefining the potential of small molecules.
Small molecules retain several intrinsic advantages that ensure their enduring foundational role: oral bioavailability, ease of manufacturing scalability, inherent stability, and the ability to access intracellular targets. These characteristics often translate into lower costs of goods and greater patient convenience. As Matern predicts, "Small molecules will remain at the foundation because they’re scalable, they’re orally delivered, they’re stable." Consequently, small molecules are likely to remain the default modality for numerous indications, particularly in widespread conditions such as metabolic and infectious diseases.
One of the most significant developments driving this renaissance is the emergence of targeted protein degradation (TPD). Unlike traditional small molecules that primarily inhibit a protein’s function, degraders such as proteolysis-targeting chimeras (PROTACs) and molecular glues hijack the cell’s own ubiquitin-proteasome system—its natural protein disposal machinery—to selectively eliminate target proteins. This revolutionary approach dramatically expands the druggable target space, making proteins that lack conventional binding pockets, or those that are too large or flexible for traditional inhibitors, now accessible. Nello Mainolfi, CEO of Kymera Therapeutics, highlighted this potential, stating, "Targeted protein degradation allows us to reach broader patient populations compared to injectable biologics. We are developing oral drugs with biologics-like activity, reaching critical signaling nodes that have been historically ‘undruggable’ with traditional inhibitors."
Another burgeoning frontier is RNA-targeting molecules. These small molecules are specifically designed to bind and modulate RNA rather than proteins. Historically, RNA was considered an "undruggable" target for small molecules, but advancements in structural biology and AI are rapidly changing this perception. These molecules hold immense potential to address targets upstream of protein expression, including transcription factors and splice sites, which are often inaccessible to both traditional small molecules and most biologics. A strong commercial validation of this approach came last year when Merck Group entered a $2 billion strategic partnership with Skyhawk Therapeutics focused on discovering novel RNA-targeting small molecules for neurological disorders.
Perhaps one of the most commercially significant trends is the push to render complex molecules orally available, including peptides and other structures that have historically required injection. The GLP-1 story serves as the highest-profile example of this transformative effort. Semaglutide, initially an injectable peptide, is now available in an oral formulation, with next-generation oral small molecule GLP-1 agonists actively in development. This innovation promises to dramatically enhance patient access and adherence. As Matern observed, "If you can make complex biological drugs orally available, you expand access, you make them stable, you can deliver them to remote corners of the world without worrying about a cold chain." Oral peptide technologies are poised to unlock a new generation of drugs that combine the targeting precision of biologics with the convenience and scalability inherent to small molecules.
Large Molecule R&D: Expanding the Therapeutic Frontier
Biologics are in the midst of an unprecedented expansion, with pipelines becoming broader, more diverse, and technically ambitious than at any previous point in the industry’s history. What began with the advent of monoclonal antibodies in the 1980s has blossomed into a sophisticated ecosystem of modalities, each offering distinct mechanisms, target classes, and benefits for specific patient populations.
The core strengths of biologics are compelling: they can be engineered to bind single targets with extraordinary precision, minimizing off-target effects. Proteins, receptors, and ligands located on the cell surface or circulating in the bloodstream are highly accessible to these large molecules. Many biologics offer long-lasting therapeutic effects, with some requiring dosing only monthly or even less frequently, significantly improving patient quality of life. From blocking specific receptors to delivering cytotoxic payloads or even editing genes, biologics provide a range of mechanisms of action often unavailable to small molecules.
Monoclonal antibodies (mAbs) remain the cornerstone of the biologic pipeline. Modern mAbs are increasingly engineered for improved half-life, reduced immunogenicity, and bispecific targeting. Bispecific antibodies, for instance, are designed to engage two distinct targets simultaneously, enabling novel mechanisms such as redirecting T cells to specifically kill tumor cells. Another critical large molecule class is antibody-drug conjugates (ADCs), which exemplify a hybrid approach by combining the exquisite targeting precision of an antibody with the potent cytotoxic efficacy of a small molecule payload.
mRNA therapies have rapidly emerged from the pandemic spotlight, diversifying into oncology vaccines, treatments for rare diseases, and infectious disease vaccines beyond COVID-19. Within the broader RNA space, siRNA (small interfering RNA) and antisense oligonucleotides (ASOs) represent powerful RNA interference approaches that silence disease-causing genes at the mRNA level. These have gained regulatory approvals in various rare disease and cardiovascular indications, demonstrating their potential to address the root causes of genetic disorders.
CAR-T cell therapies, which involve engineering a patient’s own T cells to recognize and destroy cancer cells, have been transformative in the treatment of hematologic malignancies, with active development underway for solid tumor applications. Furthermore, CRISPR and gene editing technologies are rapidly advancing, with the first approved CRISPR therapy reaching patients in 2023, marking a monumental milestone in genetic medicine.
Oncology stands as the single largest driver of biologic R&D investment, representing the therapeutic area where the most ambitious large molecule science is being deployed. ADCs, in particular, have seen a surge in approvals and late-stage pipeline activity, with over 100 ADCs currently in global clinical development. Immuno-oncology, encompassing checkpoint inhibitors, CAR-T therapies, and bispecific antibodies, continues its expansion, progressively moving from treating hematologic cancers to tackling the formidable challenge of solid tumors.
The GLP-1 Story: A Paradigm for Modality Evolution
The success of GLP-1 receptor agonists serves as a compelling case study, illustrating both the immense commercial and scientific power of large molecule R&D and the dynamic interplay between modalities. Drugs like semaglutide and tirzepatide have rapidly become some of the best-selling pharmaceuticals in history, validating peptide engineering at an unprecedented scale within the industry.
Crucially, the GLP-1 narrative also embodies lifecycle innovation—how the clinical and commercial validation of a biologic can drive subsequent small molecule development. Matern highlighted this pattern: "GLP-1 is really showing how that balance is evolving. They are a peptide-based modality — technically in the large molecule category — but the commercial success is now driving innovation across small molecules: oral delivery and combination therapy." He further explained, "I think we’ll see that pattern repeat. Historically, many therapies start as injectables because it’s technically simpler to deliver a complicated molecule that way. But once you get the validation of the biology and the commercial demand becomes clear, there’s a really strong investment incentive to invest in more convenient formats."
The journey of GLP-1 agonists, from injectable peptides to orally available small molecule formulations, is poised to become a template for future modality evolution across a multitude of therapeutic areas, emphasizing patient convenience and broader accessibility as key drivers of innovation.
Implications for Stakeholders in a Converging Landscape
The evolving landscape of pharmaceutical R&D carries significant implications for various stakeholders:
- For Large Pharma: The imperative is clear: portfolio diversification across all modalities is critical. This necessitates substantial investment in advanced data infrastructure to support AI-driven discovery and strategic acquisitions or partnerships with platform biotechs, ideally before their valuations fully reflect clinical validation. Agility in adopting new technologies and integrating diverse scientific expertise will be paramount.
- For Biotechs: While platform focus remains a strength, the most fundable and attractive propositions for partnerships will be those that combine a truly novel modality with a thoroughly validated target and a clear, pragmatic path toward oral or other convenient delivery mechanisms. Demonstrating a tangible benefit in patient experience will be a key differentiator.
- For Investors: Focus should be directed towards companies innovating in drug delivery technologies. Identifying those solving the "last-mile problem"—safely and conveniently delivering complex molecules to their intended targets—will likely yield significant returns. Understanding the long-term potential of hybrid modalities and the lifecycle innovation curve will be crucial.
- For Researchers and R&D Teams: The foundational element of modern drug discovery is robust data. Investing in Electronic Laboratory Notebooks (ELNs), developing comprehensive ontologies, and implementing structured data capture from day one are no longer optional but essential. These elements form the bedrock for effective AI integration and data-driven decision-making.
Conclusion: A Spectrum, Not a Binary
The distinction between small and large molecules is increasingly becoming a false dichotomy. The expanding "gray area" of hybrid and intermediate modalities, such as ADCs, PROTACs, and RNA-small molecule conjugates, deliberately combines the advantageous properties of both, transforming the modality question from a binary choice into a continuous spectrum.
Andreas Matern encapsulates this perspective: "I don’t see small and large molecules competing for dominance. I think there’s going to be a continued balance… small molecules will remain at the foundation because they’re scalable, they’re orally delivered, they’re stable. And biologics will probably be where we continue to expand, where things like precision and durability matter."
The most consequential change in drug discovery in a generation is the shift from empirical trial and error to data-driven prediction. Organizations are recognizing this and making substantial investments in data quality, governance, and integration to power AI-driven drug discovery pipelines. However, scientific insight alone is insufficient. The enduring challenge of drug discovery remains getting the right drug to the right target in the right patient. Breakthroughs in lipid nanoparticles, oral peptide technologies, advanced ADC linker chemistry, and next-generation formulation science represent the next wave of innovation addressing this critical delivery challenge.
Ultimately, the expansion of the therapeutic modality toolkit represents unequivocally good news for patients, for scientific advancement, and for the pharmaceutical industry as a whole. More tools translate into more addressable targets, a broader range of treatable diseases, and the potential to reach a greater number of patients globally. The true competition is not between modalities themselves, but rather between organizations that embrace this emerging complexity and those that fail to adapt to this dynamic and integrated future.
Leave a Reply